Alpine Immune Sciences Management

Management criteria checks 3/4

Alpine Immune Sciences' CEO is Mitch Gold, appointed in Jun 2016, has a tenure of 7.92 years. total yearly compensation is $2.92M, comprised of 20.5% salary and 79.5% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth €791.58K. The average tenure of the management team and the board of directors is 4.3 years and 6.1 years respectively.

Key information

Mitch Gold

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage	20.5%
CEO tenure	7.9yrs
CEO ownership	0.02%
Management average tenure	4.3yrs
Board average tenure	6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mitch Gold's remuneration changed compared to Alpine Immune Sciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$3m	US$599k	-US$32m
Sep 30 2023	n/a	n/a	-US$57m
Jun 30 2023	n/a	n/a	-US$59m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$3m	US$544k	-US$58m
Sep 30 2022	n/a	n/a	-US$54m
Jun 30 2022	n/a	n/a	-US$54m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$3m	US$523k	-US$50m
Sep 30 2021	n/a	n/a	-US$42m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$1m	US$500k	-US$28m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$33m
Mar 31 2020	n/a	n/a	-US$35m
Dec 31 2019	US$2m	US$485k	-US$42m
Sep 30 2019	n/a	n/a	-US$47m
Jun 30 2019	n/a	n/a	-US$48m
Mar 31 2019	n/a	n/a	-US$44m
Dec 31 2018	US$1m	US$400k	-US$36m
Sep 30 2018	n/a	n/a	-US$30m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$2m	US$300k	-US$8m

Compensation vs Market: Mitch's total compensation ($USD2.92M) is about average for companies of similar size in the German market ($USD2.36M).

Compensation vs Earnings: Mitch's compensation has increased whilst the company is unprofitable.

CEO

Mitch Gold (55 yo)

7.9yrs

Tenure

US$2,921,224

Compensation

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mitchell Gold	Executive Chairman & CEO	7.9yrs	US$2.92m	0.019% € 791.6k
Stanford Peng	President and Head of Research & Development	5.1yrs	US$1.75m	0.43% € 17.7m
Paul Rickey	Senior VP	7.1yrs	US$1.28m	no data
Ulrich Fuhs	VP of Finance & Chief Accounting Officer	less than a year	no data	0.044% € 1.8m
M. Yi	Chief Technology Officer	less than a year	no data	no data
Michelle Greenblatt	Director of Investor Relations & Corporate Communications	no data	no data	no data
Remy Durand	Chief Business Officer	4.3yrs	no data	0.15% € 6.1m
Andrew Sandler	Chief Medical Officer	1.8yrs	no data	no data

4.3yrs

Average Tenure

52yo

Average Age

Experienced Management: 34LA's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mitchell Gold	Executive Chairman & CEO	9.3yrs	US$2.92m	0.019% € 791.6k
Robert Conway	Independent Director	6.8yrs	US$110.21k	0.073% € 3.0m
James Topper	Independent Director	7.9yrs	US$101.46k	0% € 0
Peter Thompson	Independent Director	7.9yrs	US$103.96k	0% € 0
Rafi Ahmed	Member of Scientific Advisory Board	5.5yrs	no data	no data
Xiangmin Cui	Independent Director	5.3yrs	US$100.21k	0% € 0
Andrew Scharenberg	Scientific Advisory Board Chairman	no data	no data	no data
Christopher Peetz	Independent Director	6.1yrs	US$98.96k	0.0028% € 113.6k
John Thompson	Member of Scientific Advisory Board	5.5yrs	no data	no data
Manish Butte	Member of Scientific Advisory Board	no data	no data	no data
Paul Tumeh	Member of Scientific Advisory Board	no data	no data	no data
James Welsh	Member of Scientific Advisory Board	5.5yrs	no data	no data

6.1yrs

Average Tenure

58yo

Average Age

Experienced Board: 34LA's board of directors are considered experienced (6.1 years average tenure).

Alpine Immune Sciences Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. Announces Board Changes

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2023)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Full year 2023 earnings released: US$0.64 loss per share (vs US$1.73 loss in FY 2022)

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Insufficient new directors

Insufficient new directors

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New major risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.60 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$1.73 loss per share (vs US$1.98 loss in FY 2021)

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$0.46 loss in 2Q 2021)

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

First quarter 2022 earnings released: US$0.25 loss per share (vs US$0.45 loss in 1Q 2021)

Alpine Immune Sciences, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

Insufficient new directors

Alpine Immune Sciences, Inc. announced that it expects to receive $15 million in funding from Horizon Therapeutics Public Limited Company

Insufficient new directors

Third quarter 2021 earnings released: US$0.55 loss per share (vs US$0.28 loss in 3Q 2020)

Independent Director recently bought €84k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.53 loss in 2Q 2020)

Alpine Immune Sciences Announces First Patient Dosed in Synergy, Alpn-101 Phase 2 Lupus Clinical Trial and $45 Million in Development Milestones Achieved Under Abbvie Collaboration

Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at 2021 American Society of Clinical Oncology Virtual Annual Meeting

Alpine Immune Sciences, Inc. Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.30 loss in 1Q 2020)

Full year 2020 earnings released: US$1.34 loss per share (vs US$2.28 loss in FY 2019)

Alpine Immune Sciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021

Alpine Immune Sciences, Inc. Announces Executive Changes

New 90-day high: €11.80

Alpine Immune Sciences Appoints Natasha A. Hernday to its Board of Directors

New 90-day high: €7.70

Independent Director recently bought €68k worth of stock

Third quarter 2020 earnings released: US$0.28 loss per share

Revenue misses expectations

Alpine Immune Sciences, Inc. to Report Q3, 2020 Results on Nov 12, 2020

First half earnings released

Alpine Immune Sciences, Inc. announced that it has received $60.000012 million in funding from a group of investors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age